|
Kallikrein, Decreased Urinary Activity of
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
|
|
|
|
Kallikrein, Decreased Urinary Activity of
|
0.400 |
GeneticVariation
|
phenotype |
CLINVAR |
|
|
|
|
Acute myocardial infarction
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
(3) Individuals with the combined genotypes of ACE DD and KLK1 GG showed significantly increased risk of AMI compared with those with the combined genotypes of ACE II and KLK1 AA.
|
27329205 |
2017 |
|
Pancreatitis
|
0.200 |
Biomarker
|
disease |
RGD |
4 During pancreatitis, t-KK-like and plasma kallikrein (p-KK)-like activity in the pancreas, as well as trypsinogen activation peptide (TAP) increased significantly.
|
12770935 |
2003 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Tumour metabolites regulate tissue kallikrein in human umbilical vein endothelial cells.
|
15110992 |
2004 |
|
Kidney Diseases
|
0.050 |
Biomarker
|
group |
BEFREE |
Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways.
|
17272402 |
2007 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.
|
17629406 |
2007 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.
|
17629406 |
2007 |
|
Clear-cell metastatic renal cell carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
KLK1 has stronger expression in high grade compared to low grade clear cell RCC.
|
20128686 |
2010 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Tissue kallikrein levels are increased in type 2 diabetes, whereas statin therapy does not modify the circulating kallikrein-kinin system.
|
20225398 |
2010 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Tissue kallikrein, blood pressure regulation, and hypertension: insight from genetic kallikrein deficiency.
|
23324381 |
2013 |
|
Kidney Failure, Acute
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
KLK1 promoter polymorphisms are associated with development of AKI and adverse outcomes.
|
23635481 |
2012 |
|
Coronary Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Tissue kallikrein is related to the severity of coronary artery disease.
|
23639635 |
2013 |
|
Coronary heart disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Tissue kallikrein is related to the severity of coronary artery disease.
|
23639635 |
2013 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tissue kallikrein and kallikrein-related peptidases (KLKs) compose a family of serine endopeptidases with much clinical interest in oncology, as their potential as diagnostic and/or prognostic molecular biomarkers in several human malignancies has already been evidenced.
|
26351937 |
2016 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Kallikrein-1 (KLK1) and angiotensin-converting enzyme (ACE) are 2 key molecules in kallikrein-kinin systems and renin-angiotensin systems, respectively, which are responsible for maintaining vascular balance and stability, playing important roles in atherosclerosis.
|
27858843 |
2016 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Kallikrein-1 (KLK1) and angiotensin-converting enzyme (ACE) are 2 key molecules in kallikrein-kinin systems and renin-angiotensin systems, respectively, which are responsible for maintaining vascular balance and stability, playing important roles in atherosclerosis.
|
27858843 |
2016 |
|
Triple Negative Breast Neoplasms
|
0.010 |
Biomarker
|
disease |
BEFREE |
Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer.
|
28755528 |
2017 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer.
|
28755528 |
2017 |
|
Ischemic stroke
|
0.040 |
Biomarker
|
disease |
BEFREE |
Tissue kallikrein (TK) has been proven to elicit a variety of biological effects in ischemic stroke through its anti-inflammatory and anti-oxidant properties.
|
28810574 |
2017 |
|
Asthma
|
0.020 |
Biomarker
|
disease |
BEFREE |
KLK1, 3 and 14 are involved in asthma pathogenesis, and KLK1 could be also associated with the exacerbation of this inflammatory disease caused by rhinovirus.
|
29604204 |
2018 |
|
Inflammatory disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
KLK1, 3 and 14 are involved in asthma pathogenesis, and KLK1 could be also associated with the exacerbation of this inflammatory disease caused by rhinovirus.
|
29604204 |
2018 |
|
Rhinovirus infection
|
0.010 |
Biomarker
|
disease |
BEFREE |
KLK1, 3 and 14 are involved in asthma pathogenesis, and KLK1 could be also associated with the exacerbation of this inflammatory disease caused by rhinovirus.
|
29604204 |
2018 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Tissue kallikrein, the oldest member and kinin-releasing enzyme, and KLK3/PSA, a tumor biomarker for prostate cancer are the most prominent components of the family.
|
29885274 |
2018 |
|
Malignant neoplasm of prostate
|
0.050 |
Biomarker
|
disease |
BEFREE |
Tissue kallikrein, the oldest member and kinin-releasing enzyme, and KLK3/PSA, a tumor biomarker for prostate cancer are the most prominent components of the family.
|
29885274 |
2018 |